الفهرس 
Enhancement of dissolution rate and pharmacokinetics of meloxicam using polymeric materials
ContentsOnly 14 pages are availabe for public view
 |  | from | 175 |  |  |
| | | from | 175 | | |
Abstract
Meloxicam (MX) is a potent non-steriodal anti-inflammatory drug (NSAID) and a selective inhibitor for COX-II enzyme. MX has low aqueous solubility (belonging to biopharmaceutical classification system 2BCS3 Class II) which exhibits a slow oral absorption with delayed onset of action, causing failure to give the expected analgesic effect on the desired time. It is well-known that MX is nearly totally absorbed after oral administration, however its absorption rate is distinctly slow with Tmax value greater than 5 hours. There is a direct relation between oral absorption and the gastric emptying rate (GER) of MX because of its incomplete dissolution in stomach, which might be one of the reasons for late Meloxicam absorption. Hence, the oral administration of MX is not the treatment of choice in acute pain conditions. Targeting the production of a stable novel preparation of MX with rapid dissolution, for management of acute to moderate pain is still required. Hot melt extrusion (HME) is one of the most increasingly pharmaceutical technologies for enhancing dissolution and kinetically stabilizing the amorphous state of the drug is through the formation of solid dispersions (SDs) with the improvement of both dissolution and oral bioavailability.The versatility of hot melt extrusion (HME) for the manufacturing of different drug delivery systems has made it a promising technology that transformed the whole paradigm of pharmaceutical industry research and manufacturing. HME process offers numerous advantages over conventional approaches. as it is a solvent-free, environmental friendly (green method) process. Furthermore, HME is regarded as a continuous, highly reproducible, simple and cost-efficient technique for the scale-up production process